Jiangsu Nannong High tech Co., Ltd. is mainly composed of Nanjing Agricultural University and Jiangyin Xinjinnan Investment and Development Co., Ltd. It was established in 2000 in accordance with the modern enterprise system. It is a national high-tech enterprise specializing in the research and development, production, operation, and service of livestock and poultry vaccines. It is a key leading enterprise in agricultural industrialization in Jiangsu Province and a national level specialized and innovative "little giant" enterprise.

The company currently has 255 employees. There are 2 doctors, 25 masters, and over 60% of the total personnel have a college degree. There are 55 scientific and technological personnel engaged in new product research and development, and 35 personnel with professional titles.

• 20 terms

  Technology projects

• 15 term

  Invention Patent

• 15 term

  Certificate of new veterinary medicine

• 15 year

  Maintain a leading market share

The company has provincial-level research and development platforms such as the "Jiangsu Animal Disease Prevention and Control Bioengineering Technology Research Center", "Jiangsu Province Certified Enterprise Technology Center", "Jiangsu Province Postdoctoral Innovation Practice Base", and "Jiangsu Province Graduate Workstation", as well as municipal level research and development platforms such as the "Wuxi Academician Workstation" and "Jiangyin Academician Workstation". The company has established long-term and stable industry university research cooperation relationships with well-known domestic research institutes such as the School of Veterinary Medicine at Nanjing Agricultural University, Jiangnan University, the School of Veterinary Medicine at Yangzhou University, Jiangsu Academy of Agricultural Sciences, and Harbin Veterinary Research Institute. In recent years, we have undertaken more than 20 projects from national, provincial, and municipal science and technology departments, obtained 15 invention patents, and obtained 15 national new veterinary drug certificates.

By 2023, the company will be the only biopharmaceutical enterprise in Wuxi specializing in the production of livestock and poultry vaccines, and also the largest high-tech private enterprise in Jiangsu Province specializing in the production of livestock and poultry vaccines; With the deepening of the company's technological innovation work item by item, the company has formed a mature research and innovation system that integrates industry university research cooperation. With the support of the company's strong technical team, it continuously strengthens cooperation with well-known domestic research institutions, industry university research cooperation, and scientific research cooperation with similar enterprises to jointly develop livestock and poultry vaccine related technologies. It closely combines with the forefront of breeding and adopts the latest technologies such as reverse genetics and gene recombination to conduct new product research and development, improve market competitiveness, and currently ranks among the top fifteen in the industry in annual sales; The pig ring vaccine series products have maintained a leading market share in the country for 15 consecutive years, with the market share of recombinant Newcastle disease virus inactivated vaccines continuing to lead. The market share of swine fever live vaccines and pseudo rabies live vaccines ranks among the top in the industry; Research and innovation capabilities, with annual rankings of the top ten scientific research achievements and technological levels in the industry; The high-end market share of large-scale aquaculture groups exceeds that of imported vaccines.

In order to meet the needs of market development, the company needs to enrich its product range and expand its production capacity. The company has built a new vaccine workshop with a building area of 24200 square meters. This project has a total investment of 300 million yuan. After completion, the entire factory will have a total of 12 production lines, with an annual production capacity of 15.6 billion feathers (heads) of live animal vaccines and 1.1 billion milliliters of inactivated vaccines. The company's total assets are expected to reach 500 million yuan, which is expected to drive the development of 25700 households and bring about an annual sales revenue of about 500 million yuan for the company.

The company is committed to building a learning and innovative modern enterprise, adhering to the business philosophy of "new technology, heart service, and new benchmark" and the corporate spirit of "building oneself with morality, innovating and creating excellence, developing with sincerity, and achieving win-win results". It continuously introduces more new technologies and products urgently needed by the livestock and poultry breeding industry, providing comprehensive and high-quality services for the livestock and poultry breeding industry. The company will aim to develop China's high-tech biotechnology and achieve the industrialization of scientific and technological achievements, strengthen economic cooperation and technological exchanges between industries, achieve complementary advantages, realize the industrialization of high-tech and industrial high-tech, serve the livestock industry, prosper the rural economy, fully utilize the economic organizational form and good mechanism of the limited company, contribute to the construction of China's animal epidemic prevention system and the establishment of a livestock safety system, and create satisfactory returns for all employees.